THE PSYCHEDELIC AND KETAMINE RENAISSANCE IN THE FACE OF THE CRISIS IN MODERN PSYCHIATRY
DOI:
https://doi.org/10.31435/ijitss.2(50).2026.5605Keywords:
Depression, Psychedelics, Ketamine, Psylocybin, 5-HT2A agonism, Neuroplasticity, Bioethics, Mental HealthAbstract
Introduction: Contemporary psychiatry is grappling with a profound stagnation in innovation. It is primarily relying on the chronic management of symptoms through traditional daily-dose pharmacotherapy. The emergence of psychedelics and ketamine marks a significant departure from this model. It is offering rapid-acting, interventional alternatives that target the underlying neurobiological mechanisms of mental disorders rather than mere symptom suppression.
Purpose: The primary objective of this article is to evaluate the therapeutic potential of psychedelics and ketamine as catalysts for a new paradigm in mental healthcare. The paper aims to synthesize current knowledge on 5-HT2A receptor agonism, the development of next-generation non-hallucinogenic psychoplastogens, and the ethical-legal challenges associated with implementing these treatments in the global and Polish healthcare systems.
Methodology: This study employs a multidisciplinary literature review, integrating recent findings from neuropsychopharmacology, clinical trial outcomes, and bioethical analysis. It compares the efficacy and administration models of classic psychedelics against conventional treatments (e.g., SSRIs) and examines the socioeconomic factors influencing the democratization of these therapies.
Conclusions: The "psychedelic renaissance" necessitates the adoption of a new language for psychiatry, rooted in neuroplasticity and connectivity. To achieve widespread scalability, the field must focus on isolating the plasticity effect and utilizing short-acting tryptamines to reduce clinical resource burdens. Furthermore, for Poland to actively participate in this medical revolution, urgent legislative harmonization and robust ethical frameworks regarding patient suggestibility are required.
References
Rybakowski, J. (2025). Sixty years of neurotransmitter concepts of mood disorders. Sześćdziesiąt lat neuroprzekaźnikowych koncepcji chorób afektywnych. Psychiatria Polska, 59(5), 707–720. https://doi.org/10.12740/PP/205845
Schildkraut, J. J. (1965). The catecholamine hypothesis of affective disorders: A review of supporting evidence. The American Journal of Psychiatry, 122(5), 509–522. https://doi.org/10.1176/ajp.122.5.509
Müller-Oerlinghausen, B., & Abou-Saleh, M. T. (2019). Alec J. Coppen—A pioneering psychiatrist who discovered the pivotal role of serotonin in the pathogenesis of depression as well as the antisuicidal effect of lithium. International Journal of Bipolar Disorders, 7(1), Article 15. https://doi.org/10.1186/s40345-019-0150-3
Harmer, C. J., Duman, R. S., & Cowen, P. J. (2017). How do antidepressants work? New perspectives for refining future treatment approaches. The Lancet Psychiatry, 4(5), 409–418. https://doi.org/10.1016/S2215-0366(17)30015-9
Wong, D. T., Horng, J. S., Bymaster, F. P., Hauser, K. L., & Molloy, B. B. (1974). A selective inhibitor of serotonin uptake: Lilly 110140, 3-(p-trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine. Life Sciences, 15(3), 471–479. https://doi.org/10.1016/0024-3205(74)90345-2
World Health Organization. (2025, August 29). Depressive disorder (depression). https://www.who.int/news-room/fact-sheets/detail/depression
GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. (2017). Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: A systematic analysis for the Global Burden of Disease Study 2016. The Lancet, 390(10100), 1211–1259. https://doi.org/10.1016/S0140-6736(17)32154-2
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., McGrath, P. J., Rosenbaum, J. F., Sackeim, H. A., Kupfer, D. J., Luther, J., & Fava, M. (2006). Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. The American Journal of Psychiatry, 163(11), 1905–1917. https://doi.org/10.1176/ajp.2006.163.11.1905
Al-Harbi, K. S. (2012). Treatment-resistant depression: Therapeutic trends, challenges, and future directions. Patient Preference and Adherence, 6, 369–388. https://doi.org/10.2147/PPA.S29716
Moncrieff, J., Cooper, R. E., Stockmann, T., Amendola, S., Hengartner, M. P., & Horowitz, M. A. (2022). The serotonin theory of depression: A systematic umbrella review of the evidence. Molecular Psychiatry, 28, 3243–3256. https://doi.org/10.1038/s41380-022-01661-0
Plöderl, M., Lyus, R., Horowitz, M. A., & Moncrieff, J. (2025). The loss of efficacy of fluoxetine in pediatric depression: Explanations, lack of acknowledgment, and implications for other treatments. Journal of Clinical Epidemiology, Article 112016. https://doi.org/10.1016/j.jclinepi.2025.112016
Aftab, A. (2022, November 20). The case for antidepressants in 2022. Psychiatry at the Margins. https://www.psychiatrymargins.com/p/the-case-for-antidepressants-in-2022
Castrén, E., & Monteggia, L. M. (2021). Brain-derived neurotrophic factor signaling in depression and antidepressant action. Biological Psychiatry, 90(2), 128–136. https://doi.org/10.1016/j.biopsych.2021.05.008
Taylor, J. R., DiLeone, R. J., & Picciotto, M. R. (2020). Ronald S. Duman, PhD (1954–2020). Nature Neuroscience, 23(5), 595. https://doi.org/10.1038/s41593-020-0629-3
McEwen, B. S. (2016). Stress-induced remodeling of hippocampal CA3 pyramidal neurons. Brain Research, 1645, 50–54. https://doi.org/10.1016/j.brainres.2015.12.043
Moliner, R., Girych, M., Brunello, C. A., Kovaleva, V., Biojone, C., Enkavi, G., Antenucci, L., Kot, E. F., Goncharuk, S. A., Kaurinkoski, K., Kuutti, M., Fred, S. M., Elsilä, L. V., Sakson, S., Cannarozzo, C., Diniz, C. R. A. F., Seiffert, N., Rubiolo, A., Haapaniemi, H., Meshi, E., et al. (2023). Psychedelics promote plasticity by directly binding to BDNF receptor TrkB. Nature Neuroscience, 26(6), 1032–1041. https://doi.org/10.1038/s41593-023-01316-5
Azarias, F. R., Almeida, G. H. D. R., de Melo, L. F., Rici, R. E. G., & Maria, D. A. (2025). The journey of the default mode network: Development, function, and impact on mental health. Biology, 14(4), Article 395. https://doi.org/10.3390/biology14040395
Katayama, N., Shinagawa, K., Hirano, J., Kobayashi, Y., Nakagawa, A., Umeda, S., Kamiya, K., Tajima, M., Amano, M., Nogami, W., Ihara, S., Noda, S., Terasawa, Y., Kikuchi, T., Mimura, M., & Uchida, H. (2025). Dynamic neural network modulation associated with rumination in major depressive disorder: A prospective observational comparative analysis of cognitive behavioral therapy and pharmacotherapy. Translational Psychiatry, 15(1). https://doi.org/10.1038/s41398-025-03489-y
Hamilton, J. P., Farmer, M., Fogelman, P., & Gotlib, I. H. (2015). Depressive rumination, the default-mode network, and the dark matter of clinical neuroscience. Biological Psychiatry, 78(4), 224–230. https://doi.org/10.1016/j.biopsych.2015.02.020
Carhart-Harris, R. L. (2018). The entropic brain—Revisited. Neuropharmacology, 142, 167–178. https://doi.org/10.1016/j.neuropharm.2018.03.010
Gattuso, J. J., Perkins, D., Ruffell, S., Lawrence, A. J., Hoyer, D., Jacobson, L. H., Timmermann, C., Castle, D., Rossell, S. L., Downey, L. A., Pagni, B. A., Galvão-Coelho, N. L., Nutt, D., & Sarris, J. (2023). Default mode network modulation by psychedelics: A systematic review. The International Journal of Neuropsychopharmacology, 26(3), 155–188. https://doi.org/10.1093/ijnp/pyac074
Hofmann, A. (2019). LSD, my problem child; and, Insights/outlooks. Beckley Foundation.
Osmond, H. (1957). A review of the clinical effects of psychotomimetic agents. Annals of the New York Academy of Sciences, 66(3), 418–434. https://doi.org/10.1111/j.1749-6632.1957.tb40738.x
Grof, S. (1979). Realms of the human unconscious: Observations from LSD research. Souvenir Press.
Krebs, T. S., & Johansen, P. Ø. (2012). Lysergic acid diethylamide (LSD) for alcoholism: Meta-analysis of randomized controlled trials. Journal of Psychopharmacology, 26(7), 994–1002. https://doi.org/10.1177/0269881112439253
Gałecki, P., Szulc, A., & Urban, E. (2023). Psychiatria. Edra Urban & Partner.
Reither, E. J. (2025). The Harvard Psilocybin Project 1960–1963.
Belouin, S. J., & Henningfield, J. E. (2018). Psychedelics: Where we are now, why we got here, what we must do. Neuropharmacology, 142, 7–19. https://doi.org/10.1016/j.neuropharm.2018.02.018
Nutt, D. J. (2025). Drug development in psychiatry: 50 years of failure and how to resuscitate it. The Lancet Psychiatry, 12(3), 228–238. https://doi.org/10.1016/S2215-0366(24)00370-5
Krystal, J. H., Kavalali, E. T., & Monteggia, L. M. (2024). Ketamine and rapid antidepressant action: New treatments and novel synaptic signaling mechanisms. Neuropsychopharmacology, 49, 41–50. https://doi.org/10.1038/s41386-023-01629-w
Reber, A. (2016). Airway characteristics and safe management of spontaneously breathing patients: Risks of sedation and analgesia and changes in wakefulness. International Journal of Clinical Medicine, 7(11), 726–735. https://doi.org/10.4236/ijcm.2016.711079
McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., Iosifescu, D. V., Lopez Jaramillo, C., Kasper, S., Kratiuk, K., Lee, J. G., Lee, Y., Lui, L. M. W., Mansur, R. B., Papakostas, G. I., Subramaniapillai, M., et al. (2021). Synthesizing the evidence for ketamine and esketamine in treatment-resistant depression: An international expert opinion on the available evidence and implementation. The American Journal of Psychiatry, 178(5), 383–399. https://doi.org/10.1176/appi.ajp.2020.20081251
Rang, H., Dale, M., Ritter, J., Flower, R., & Henderson, G. (2020). Rang and Dale’s pharmacology (9th ed., Polish ed., pp. 578–579, 667). Elsevier Churchill Livingstone; Edra Urban & Partner.
Zanos, P., & Gould, T. D. (2018). Mechanisms of ketamine action as an antidepressant. Molecular Psychiatry, 23(4), 801–811. https://doi.org/10.1038/mp.2017.255
Duman, R. S., Aghajanian, G. K., Sanacora, G., & Krystal, J. H. (2016). Synaptic plasticity and depression: New insights from stress and rapid-acting antidepressants. Nature Medicine, 22(3), 238–249. https://doi.org/10.1038/nm.4050
Pothula, S., Kato, T., Liu, R. J., Wu, M., Gerhard, D., Shinohara, R., Sliby, A. N., Chowdhury, G. M. I., Behar, K. L., Sanacora, G., Banerjee, P., & Duman, R. S. (2021). Cell-type specific modulation of NMDA receptors triggers antidepressant actions. Molecular Psychiatry, 26(9), 5097–5111. https://doi.org/10.1038/s41380-020-0796-3
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997). Activation of glutamatergic neurotransmission by ketamine: A novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. The Journal of Neuroscience, 17(8), 2921–2927. https://doi.org/10.1523/jneurosci.17-08-02921.1997
Anand, A., Mathew, S. J., Sanacora, G., Murrough, J. W., Goes, F. S., Altinay, M., Aloysi, A. S., Asghar-Ali, A. A., Barnett, B. S., Chang, L. C., Collins, K. A., Costi, S., Iqbal, S., Jha, M. K., Krishnan, K., Malone, D. A., Nikayin, S., Nissen, S. E., Ostroff, R. B., et al. (2023). Ketamine versus ECT for nonpsychotic treatment-resistant major depression. The New England Journal of Medicine, 388(25), 2315–2325. https://doi.org/10.1056/NEJMoa2302399
Li, N., Lee, B., Liu, R. J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X. Y., Aghajanian, G., & Duman, R. S. (2010). mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science, 329(5994), 959–964. https://doi.org/10.1126/science.1190287
Park, H., & Poo, M. M. (2013). Neurotrophin regulation of neural circuit development and function. Nature Reviews Neuroscience, 14(1), 7–23. https://doi.org/10.1038/nrn3379
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P. F., Kavalali, E. T., & Monteggia, L. M. (2011). NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature, 475(7354), 91–95. https://doi.org/10.1038/nature10130
Duman, R. S., & Monteggia, L. M. (2006). A neurotrophic model for stress-related mood disorders. Biological Psychiatry, 59(12), 1116–1127. https://doi.org/10.1016/j.biopsych.2006.02.013
Casarotto, P. C., Girych, M., Fred, S. M., Kovaleva, V., Moliner, R., Enkavi, G., Biojone, C., Cannarozzo, C., Sahu, M. P., Kaurinkoski, K., Brunello, C. A., Steinzeig, A., Winkel, F., Patil, S., Vestring, S., Serchov, T., Diniz, C. R. A. F., Laukkanen, L., Cardon, I., Antila, H., et al. (2021). Antidepressant drugs act by directly binding to TRKB neurotrophin receptors. Cell, 184(5), 1299–1313.e19. https://doi.org/10.1016/j.cell.2021.01.034
Daly, E. J., Singh, J. B., Fedgchin, M., Cooper, K., Lim, P., Shelton, R. C., Thase, M. E., Winokur, A., Van Nueten, L., Manji, H., & Drevets, W. C. (2018). Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: A randomized clinical trial. JAMA Psychiatry, 75(2), 139–148. https://doi.org/10.1001/jamapsychiatry.2017.3739
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., Rickard, J. A., Forbes, B., Feilding, A., Taylor, D., Curran, H. V., & Nutt, D. J. (2018). Psilocybin with psychological support for treatment-resistant depression: Six-month follow-up. Psychopharmacology, 235(2), 399–408. https://doi.org/10.1007/s00213-017-4771-x
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Journal of Psychopharmacology, 30(12), 1181–1197. https://doi.org/10.1177/0269881116675513
Vollenweider, F. X., & Kometer, M. (2010). The neurobiology of psychedelic drugs: Implications for the treatment of mood disorders. Nature Reviews Neuroscience, 11(9), 642–651. https://doi.org/10.1038/nrn2884
Carhart-Harris, R. L., Erritzoe, D., Williams, T., Stone, J. M., Reed, L. J., Colasanti, A., Tyacke, R. J., Leech, R., Malizia, A. L., Murphy, K., Hobden, P., Evans, J., Feilding, A., Wise, R. G., & Nutt, D. J. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings of the National Academy of Sciences of the United States of America, 109(6), 2138–2143. https://doi.org/10.1073/pnas.1119598109
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., Taylor, D., Pilling, S., Curran, V. H., & Nutt, D. J. (2016). Psilocybin with psychological support for treatment-resistant depression: An open-label feasibility study. The Lancet Psychiatry, 3(7), 619–627. https://doi.org/10.1016/S2215-0366(16)30065-7
Meunier, D., Lambiotte, R., & Bullmore, E. T. (2010). Modular and hierarchically modular organization of brain networks. Frontiers in Neuroscience, 4, Article 200. https://doi.org/10.3389/fnins.2010.00200
Petri, G., Expert, P., Turkheimer, F., Carhart-Harris, R., Nutt, D., Hellyer, P. J., & Vaccarino, F. (2014). Homological scaffolds of brain functional networks. Journal of the Royal Society Interface, 11(101), Article 20140873. https://doi.org/10.1098/rsif.2014.0873
Mithoefer, M. C., Mithoefer, A. T., Feduccia, A. A., Jerome, L., Wagner, M., Wymer, J., Holland, J., Hamilton, S., Yazar-Klosinski, B., Emerson, A., & Doblin, R. (2018). 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: A randomised, double-blind, dose-response, phase 2 clinical trial. The Lancet Psychiatry, 5(6), 486–497. https://doi.org/10.1016/S2215-0366(18)30135-4
Phelps, J. (2017). Developing guidelines and competencies for the training of psychedelic therapists. Journal of Humanistic Psychology, 57(5), 450–487. https://doi.org/10.1177/0022167817711304
Johnson, M., Richards, W., & Griffiths, R. (2008). Human hallucinogen research: Guidelines for safety. Journal of Psychopharmacology, 22(6), 603–620. https://doi.org/10.1177/0269881108093587
Popova, V., Daly, E. J., Trivedi, M., Cooper, K., Lane, R., Lim, P., Mazzucco, C., Hough, D., Thase, M. E., Shelton, R. C., Molero, P., Vieta, E., Bajbouj, M., Manji, H., Drevets, W. C., & Singh, J. B. (2019). Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: A randomized double-blind active-controlled study. The American Journal of Psychiatry, 176(6), 428–438. https://doi.org/10.1176/appi.ajp.2019.19020172
Sanacora, G., Frye, M. A., McDonald, W., Mathew, S. J., Turner, M. S., Schatzberg, A. F., Summergrad, P., Nemeroff, C. B., & American Psychiatric Association Council of Research Task Force on Novel Biomarkers and Treatments. (2017). A consensus statement on the use of ketamine in the treatment of mood disorders. JAMA Psychiatry, 74(4), 399–405. https://doi.org/10.1001/jamapsychiatry.2017.0080
Halpern, J. H., & Pope, H. G., Jr. (2003). Hallucinogen persisting perception disorder: What do we know after 50 years? Drug and Alcohol Dependence, 69(2), 109–119. https://doi.org/10.1016/s0376-8716(02)00306-x
Carbonaro, T. M., Bradstreet, M. P., Barrett, F. S., MacLean, K. A., Jesse, R., Johnson, M. W., & Griffiths, R. R. (2016). Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. Journal of Psychopharmacology, 30(12), 1268–1278. https://doi.org/10.1177/0269881116662634
Szigeti, B., Weiss, B., Rosas, F. E., Erritzoe, D., Nutt, D., & Carhart-Harris, R. (2024). Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression. Psychological Medicine, 54(8), 1717–1724. https://doi.org/10.1017/S0033291723003653
Price, J., Cole, V., & Goodwin, G. M. (2009). Emotional side-effects of selective serotonin reuptake inhibitors: Qualitative study. The British Journal of Psychiatry, 195(3), 211–217. https://doi.org/10.1192/bjp.bp.108.051110
Carhart-Harris, R., Giribaldi, B., Watts, R., Baker-Jones, M., Murphy-Beiner, A., Murphy, R., Martell, J., Blemings, A., Erritzoe, D., & Nutt, D. J. (2021). Trial of psilocybin versus escitalopram for depression. The New England Journal of Medicine, 384(15), 1402–1411. https://doi.org/10.1056/NEJMoa2032994
Serretti, A., & Chiesa, A. (2009). Treatment-emergent sexual dysfunction related to antidepressants: A meta-analysis. Journal of Clinical Psychopharmacology, 29(3), 259–266. https://doi.org/10.1097/JCP.0b013e3181a5233f
Gafoor, R., Booth, H. P., & Gulliford, M. C. (2018). Antidepressant utilisation and incidence of weight gain during 10 years’ follow-up: Population based cohort study. BMJ, 361, Article k1951. https://doi.org/10.1136/bmj.k1951
Goldberg, S. B., Pace, B. T., Nicholas, C. R., Raison, C. L., & Hutson, P. R. (2020). The experimental effects of psilocybin on symptoms of anxiety and depression: A meta-analysis. Psychiatry Research, 284, Article 112749. https://doi.org/10.1016/j.psychres.2020.112749
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., Duim, W. C., Dennis, M. Y., McAllister, A. K., Ori-McKenney, K. M., Gray, J. A., & Olson, D. E. (2018). Psychedelics promote structural and functional neural plasticity. Cell Reports, 23(11), 3170–3182. https://doi.org/10.1016/j.celrep.2018.05.022
Davis, A. K., & Griffiths, R. R. (2021). Errors in a response rate and in effect sizes in study of psilocybin-assisted therapy for major depressive disorder. JAMA Psychiatry. https://doi.org/10.1001/jamapsychiatry.2020.4638
Rhead, J. (2014). The psychedelic explorer’s guide: Safe, therapeutic, and sacred journeys. Journal of Psychoactive Drugs, 46(4), 347–348. https://doi.org/10.1080/02791072.2014.948329
Szigeti, B., Kartner, L., Blemings, A., Rosas, F., Feilding, A., Nutt, D. J., Carhart-Harris, R. L., & Erritzoe, D. (2021). Self-blinding citizen science to explore psychedelic microdosing. eLife, 10, Article e62878. https://doi.org/10.7554/eLife.62878
Trautmann, S., Rehm, J., & Wittchen, H. U. (2016). The economic costs of mental disorders: Do our societies react appropriately to the burden of mental disorders? EMBO Reports, 17(9), 1245–1249. https://doi.org/10.15252/embr.201642951
Greenberg, P., Chitnis, A., Louie, D., Suthoff, E., Chen, S. Y., Maitland, J., Gagnon-Sanschagrin, P., Fournier, A. A., & Kessler, R. C. (2023). The economic burden of adults with major depressive disorder in the United States (2019). Advances in Therapy, 40(10), 4460–4479. https://doi.org/10.1007/s12325-023-02622-x
Therapeutic Goods Administration. (2023, February 3). Change to classification of psilocybin and MDMA to enable prescribing by authorised psychiatrists. https://www.tga.gov.au/news/media-releases/change-classification-psilocybin-and-mdma-enable-prescribing-authorised-psychiatrists
Oregon Health Authority. (n.d.). Oregon Psilocybin Services. State of Oregon. https://www.oregon.gov/oha/PH/PREVENTIONWELLNESS/Pages/Oregon-Psilocybin-Services.aspx
Amabile, J., & Fenberg, S. (n.d.). Natural medicine regulation and legalization. Colorado General Assembly. https://leg.colorado.gov/bills/sb23-290
Ustawa z dnia 29 lipca 2005 r. o przeciwdziałaniu narkomanii. (n.d.). Internetowy System Aktów Prawnych. https://isap.sejm.gov.pl/isap.nsf/DocDetails.xsp?id=wdu20051791485
Ministerstwo Zdrowia. (2024). Obwieszczenie Ministra Zdrowia z dnia 18 marca 2024 r. w sprawie wykazu refundowanych leków, środków spożywczych specjalnego przeznaczenia żywieniowego oraz wyrobów medycznych na 1 kwietnia 2024 r. https://www.gov.pl/web/zdrowie/obwieszczenie-ministra-zdrowia-z-dnia-18-marca-2024-r-w-sprawie-wykazu-refundowanych-lekow-srodkow-spozywczych-specjalnego-przeznaczenia-zywieniowego-oraz-wyrobow-medycznych
Medexpress.pl. (2026). B.147. nowy od 07-2023 [Word document]. https://www.medexpress.pl/documents/73/B.147._nowy_od_07-2023.docx
European Medicines Agency. (2023, December 18). EMA multi-stakeholder workshop on psychedelics—Towards an EU regulatory framework. https://www.ema.europa.eu/en/events/ema-multi-stakeholder-workshop-psychedelics-towards-eu-regulatory-framework#event-summary-64458
Cameron, L. P., Tombari, R. J., Lu, J., Pell, A. J., Hurley, Z. Q., Ehinger, Y., Vargas, M. V., McCarroll, M. N., Taylor, J. C., Myers-Turnbull, D., Liu, T., Yaghoobi, B., Laskowski, L. J., Anderson, E. I., Zhang, G., Viswanathan, J., Brown, B. M., Tjia, M., Dunlap, L. E., & Rabow, Z. T. (2020). A non-hallucinogenic psychedelic analogue with therapeutic potential. Nature, 589, 474–479. https://doi.org/10.1038/s41586-020-3008-z
Olson, D. E. (2018). Psychoplastogens: A promising class of plasticity-promoting neurotherapeutics. Journal of Experimental Neuroscience, 12, Article 1179069518800508. https://doi.org/10.1177/1179069518800508
Yaden, D. B., & Griffiths, R. R. (2020). The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacology & Translational Science, 4(2), 568–572. https://doi.org/10.1021/acsptsci.0c00194
Uthaug, M. V., Lancelotta, R., van Oorsouw, K., Kuypers, K. P. C., Mason, N., Rak, J., Šuláková, A., Jurok, R., Maryška, M., Kuchař, M., Páleníček, T., Riba, J., & Ramaekers, J. G. (2019). A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms. Psychopharmacology, 236(9), 2653–2666. https://doi.org/10.1007/s00213-019-05236-w
Reckweg, J. T., Uthaug, M. V., Szabo, A., Davis, A. K., Lancelotta, R., Mason, N. L., & Ramaekers, J. G. (2022). The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT). Journal of Neurochemistry, 162(1), 128–146. https://doi.org/10.1111/jnc.15587
Milton, H. (2022). Books: What happened to you? Conversations on trauma, resilience, and healing. British Journal of General Practice, 72(716), 125. https://doi.org/10.3399/bjgp22x718709
Mitchell, J. M., Bogenschutz, M., Lilienstein, A., Harrison, C., Kleiman, S., Parker-Guilbert, K., Ot’alora G, M., Garas, W., Paleos, C., Gorman, I., Nicholas, C., Mithoefer, M., Carlin, S., Poulter, B., Mithoefer, A., Quevedo, S., Wells, G., Klaire, S. S., van der Kolk, B., Tzarfaty, K., et al. (2023). MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study. Focus, 21(3), 315–328. https://doi.org/10.1176/appi.focus.23021011
Carhart-Harris, R. L., & Goodwin, G. M. (2017). The therapeutic potential of psychedelic drugs: Past, present, and future. Neuropsychopharmacology, 42(11), 2105–2113. https://doi.org/10.1038/npp.2017.84
Cooper, C. (2013, June 12). “The worst case of scientific censorship since the Catholic Church banned the works of Galileo”: Scientists call for drugs to be legalised to allow proper study of their properties. The Independent. https://www.independent.co.uk/news/science/the-worst-case-of-scientific-censorship-since-the-catholic-church-banned-the-works-of-galileo-scientists-call-for-drugs-to-be-legalised-to-allow-proper-study-of-their-properties-8654514.html
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Julia Osipowska, Marlena Kwolek, Alicja Judzińska, Bartosz Piech, Kamila Sobczyńska, Justyna Ignarska, Magda Terbosh, Sabina Kubicz-Mzabi, Emilia Trojanowska, Magdalena Dubaj
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
How to Cite
